Magenta Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Magenta Therapeutics generated cash of -$67,090,000, which is less than the previous year. Cash used in financing activities reached the amount of $2,878,000 last year. Net change in cash is therefore -$74,024,000.
Cash Flow
| 2016 | -6.52M | -139K | 10.71M |
|---|---|---|---|
| 2017 | -22.26M | -2.33M | 71.48M |
| 2018 | -41.88M | -91.70M | 142.14M |
| 2019 | -57.10M | 1.53M | 62.29M |
| 2020 | -64.02M | -10.63M | 67.73M |
| 2021 | -59.53M | 43.42M | 89.60M |
| 2022 | -67.09M | -9.81M | 2.87M |
MGTA Cash Flow Statement (2016 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 133.43M | 59.93M | 66.85M | 60.12M | 51.56M | 4.51M | 500K |
Operating activities | |||||||
Net income | -76.46M | -71.13M | -74.93M | -76.76M | -57.51M | -35.49M | -9.43M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 1.92M | 2.02M | 1.97M | 1.84M | 875K | 376K | 6K |
Stock-based compensation expense | 7.02M | 10.30M | 9.94M | 10.00M | 10.70M | 2.25M | 662K |
| Deferred income tax benefit | 7.02M | 10.30M | 9.94M | 10.00M | 10.70M | 2.25M | 662K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -801K | -720K | 948K | 145K | 2.5M | -1.12M | 1.00M |
Cash generated by operating activities | -67.09M | -59.53M | -64.02M | -57.10M | -41.88M | -22.26M | -6.52M |
Investing activities | |||||||
Purchases Of Investments | -69.49M | -45.30M | -95.73M | -144.37M | -84.04M | 0 | 0 |
Investments In Property Plant And Equipment | -314K | -1.26M | -400K | -3.06M | -7.67M | -2.19M | -139K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -9.81M | 43.42M | -10.63M | 1.53M | -91.70M | -2.33M | -139K |
Financing activities | |||||||
Common Stock Issued | 2.90M | 0 | 64.86M | 60.87M | 93M | 4K | 13K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 115K | 141K | 104K | 0 | -88K | -213K | -107K |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 2.87M | 89.60M | 67.73M | 62.29M | 142.14M | 71.48M | 10.71M |
Net Change In Cash | -74.02M | 73.49M | -6.91M | 6.72M | 8.55M | 46.88M | 4.04M |
Cash at end of period | 59.40M | 133.43M | 59.93M | 66.85M | 60.12M | 51.40M | 4.54M |
| Data source | Data source | Data source | Data source | Data source |